Holdings of Elmind Capital, LP
30 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 72.3 % of the equity sleeve
Sector breakdown
- Health care 2.7 %
- Unattributed 97.3 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|
| 1 | US | 29 | 326.6M $ | 98.33 % |
| 2 | FR | 1 | 5.5M $ | 1.67 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|
| 1 | Cogent Biosciences Inc | 1,170,740 | 45.1M $ | |
| 2 | Syndax Pharmaceuticals Inc | 1,855,000 | 43.3M $ | |
| 3 | Celldex Therapeutics Inc | 865,000 | 27.4M $ | |
| 4 | CytomX Therapeutics Inc | 4,550,000 | 21.4M $ | |
| 5 | KalVista Pharmaceuticals Inc | 1,021,300 | 20.6M $ | |
| 6 | CG oncology Inc | 291,800 | 19.7M $ | |
| 7 | Vera Therapeutics Inc | 482,500 | 19.4M $ | |
| 8 | Vaxcyte Inc | 316,500 | 18.4M $ | |
| 9 | Tyra Biosciences Inc | 350,000 | 13.4M $ | |
| 10 | Beam Therapeutics Inc | 476,338 | 11.4M $ | |
| 11 | Viridian Therapeutics Inc | 534,931 | 10.5M $ | |
| 12 | BioCryst Pharmaceuticals Inc | 1,000,000 | 9.5M $ | |
| 13 | United Therapeutics Corp | 15,000 | 8.9M $ | |
| 14 | Cullinan Therapeutics Inc | 530,000 | 7.5M $ | |
| 15 | Nurix Therapeutics Inc | 460,000 | 7.1M $ | |
| 16 | MBX Biosciences Inc | 211,000 | 6.3M $ | |
| 17 | Krystal Biotech Inc | 22,000 | 5.7M $ | |
| 18 | DBV Technologies SA | 265,000 | 5.5M $ | |
| 19 | Relay Therapeutics Inc | 536,946 | 5.3M $ | |
| 20 | Travere Therapeutics Inc | 177,600 | 5.3M $ | |
| 21 | Protagonist Therapeutics Inc | 38,000 | 4M $ | |
| 22 | Alumis Inc | 130,000 | 2.9M $ | |
| 23 | BioMarin Pharmaceutical Inc | 47,000 | 2.7M $ | |
| 24 | Design Therapeutics Inc | 207,900 | 2.2M $ | |
| 25 | Apellis Pharmaceuticals Inc | 50,000 | 2M $ | |
| 26 | Alector Inc | 900,000 | 1.9M $ | |
| 27 | Immunocore Holdings PLC | 58,248 | 1.8M $ | |
| 28 | Amylyx Pharmaceuticals Inc | 112,000 | 1.6M $ | |
| 29 | Supernus Pharmaceuticals Inc | 20,000 | 1M $ | |
| 30 | Edgewise Therapeutics Inc | 10,000 | 315K $ | |